Home/Filings/4/0001209191-22-026425
4//SEC Filing

Rangwala Reshma 4

Accession 0001209191-22-026425

CIK 0001503802other

Filed

May 1, 8:00 PM ET

Accepted

May 2, 5:01 PM ET

Size

7.5 KB

Accession

0001209191-22-026425

Insider Transaction Report

Form 4
Period: 2022-04-29
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
  • Award

    Common Stock

    2022-04-29+65,00065,000 total
  • Award

    Stock Option (right to buy)

    2022-04-29+100,000100,000 total
    Exercise: $6.10Exp: 2032-04-28Common Stock (100,000 underlying)
Footnotes (2)
  • [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning April 29, 2023.
  • [F2]This option was granted on April 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on April 29, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001825322

Filing Metadata

Form type
4
Filed
May 1, 8:00 PM ET
Accepted
May 2, 5:01 PM ET
Size
7.5 KB